within Pharmacolibrary.Drugs.ATC.B;

model B05BB03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666665e-06,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Trometamol</td></tr><tr><td>ATC code:</td><td>B05BB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trometamol (also known as tromethamine or THAM) is an organic amine proton acceptor used primarily as an intravenous buffer agent in the management of metabolic acidosis, especially in critical care settings and during certain surgical procedures. It is not widely used as a routine treatment and its clinical use today is limited.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans after intravenous administration, as direct published PK models or comprehensive parameter sets for trometamol in humans are not available.</p><h4>References</h4><ol><li><p>Wu, M, et al., &amp; Ding, Y (2020). Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design. <i>CNS drugs</i> 34(8) 867â€“877. DOI:<a href=\"https://doi.org/10.1007/s40263-020-00739-z\">10.1007/s40263-020-00739-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32700191/\">https://pubmed.ncbi.nlm.nih.gov/32700191</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end B05BB03;
